Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
08:18:57 EST Sun 08 Feb 2026
Enter Symbol
or Name
USA
CA



Q:RLMD - RELMADA THERAPEUTICS INC - https://www.relmada.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
RLMD - Q0.13.39·4.161.13.88+0.287.8473.61,5873,5913.61  3.95  3.605.12  0.240419:52:29Jan 1215 min RT 2¢

Recent Trades - Last 10 of 3591
Time ETExPriceChangeVolume
19:52:29Q3.94850.34855,220
19:32:31Q3.870.2768
19:32:31Q3.870.271
16:10:04Q3.880.281
16:10:04Q3.880.281
16:04:54Q3.880.281
16:04:54Q3.880.281
16:04:17Q3.880.281
16:04:15Q3.880.281
16:04:15Q3.880.281

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-12 07:00U:RLMDNews ReleaseRelmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications
2025-12-03 07:30U:RLMDNews ReleaseRelmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology
2025-11-13 16:01U:RLMDNews ReleaseRelmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates
2025-11-07 07:30U:RLMDNews ReleaseRelmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025
2025-11-04 07:10U:RLMDNews ReleaseRelmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
2025-11-04 07:01U:RLMDNews ReleaseRelmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer
2025-10-07 07:30U:RLMDNews ReleaseRelmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01
2025-09-16 09:00U:RLMDNews ReleaseRelmada Regains Compliance with Nasdaq Minimum Bid Price Requirement
2025-09-10 07:15U:RLMDNews ReleaseRelmada Issues Mid-Year CEO Letter to Shareholders
2025-08-07 16:05U:RLMDNews ReleaseRelmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC
2025-07-31 07:00U:RLMDNews ReleaseRelmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025
2025-07-15 08:00U:RLMDNews ReleaseRelmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01
2025-07-09 08:00U:RLMDNews ReleaseDIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors
2025-06-17 07:00U:RLMDNews ReleaseRelmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology
2025-05-12 16:01U:RLMDNews ReleaseRelmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
2025-05-08 07:30U:RLMDNews ReleaseRelmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
2025-04-28 13:39U:RLMDNews ReleaseRelmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025
2025-04-27 09:00U:RLMDNews ReleaseUPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025
2025-04-24 08:00U:RLMDNews ReleaseRelmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data
2025-04-14 08:42U:RLMDNews ReleaseUPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025